Evidence that (-)-7-hydroxy-4′-dimethylheptyl-cannabidiol activates a non-CB1, non-CB2, non-TRPV1 target in the mouse vas deferens

Neuropharmacology

Volumn 48, Issue 8 SPEC. ISS., 2005, Pages 1139-1146

  Pertwee, Roger G ^a   Thomas, Adèle ^a   Stevenson, Lesley A ^a   Maor, Yehoshua ^b   Mechoulam, Raphael ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

( ) 7 hydroxy 4 dimethylheptyl cannabidiol (7 OH DMH CBD); Cannabidiol; Gi o protein sequestration; Mouse vas deferens; R (+) WIN55212; Yohimbine

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 7 HYDROXY 4' DIMETHYLHEPTYLCANNABIDIOL; ADENOSINE TRIPHOSPHATE; ALPHA ADRENERGIC RECEPTOR; CANNABIDIOL; CANNABIDIOL DERIVATIVE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CAPSAZEPINE; GUANINE NUCLEOTIDE BINDING PROTEIN; NALOXONE; OPIATE RECEPTOR; PHENYLEPHRINE; RIMONABANT; RUTHENIUM RED; UNCLASSIFIED DRUG; YOHIMBINE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; MALE; MOUSE; MUSCLE CONTRACTION; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; VAS DEFERENS;

EID: 19444386763     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2005.01.010     Document Type: Article

References (36)

1. T. Bisogno, L. Hanus, L. De Petrocellis, S. Tchilibon, D.E. Ponde, I. Brandi, A.S. Moriello, J.B. Davis, R. Mechoulam, and V. Di Marzo Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide Br. J. Pharmacol. 134 2001 845 852
2. M.A. ElSohly Chemical constituents of cannabis F. Grotenhermen E. Russo Cannabis and cannabinoids. Pharmacology, toxicology and therapeutic potential 2002 Haworth Press, Inc. New York 27 36
3. W.R. Ford, S.A. Honan, R. White, and C.R. Hiley Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts Br. J. Pharmacol. 135 2002 1191 1198
4. N. Hájos, and T.F. Freund Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers Neuropharmacology 43 2002 503 510
5. N. Hájos, C. Ledent, and T.F. Freund Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus Neuroscience 106 2001 1 4
6. W.-S.V. Ho, and C.R. Hiley Vasodilator actions of abnormal-cannabidiol in rat isolated small mesenteric artery Br. J. Pharmacol. 138 2003 1320 1332
7. A.C. Howlett, F. Barth, T.I. Bonner, G. Cabral, P. Casellas, W.A. Devane, C.C. Felder, M. Herkenham, K. Mackie, B.R. Martin, R. Mechoulam, and R.G. Pertwee International Union of Pharmacology. XXVII. Classification of cannabinoid receptors Pharmacol. Rev. 54 2002 161 202
8. Z. Járai, J.A. Wagner, K. Varga, K.D. Lake, D.R. Compton, B.R. Martin, A.M. Zimmer, T.I. Bonner, N.E. Buckley, E. Mezey, R.K. Razdan, A. Zimmer, and G. Kunos Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors Proc. Natl Acad. Sci. U.S.A. 96 1999 14136 14141
9. 1 cannabinoid receptor J. Pharmacol. Exp. Ther. 308 2004 880 886
10. 9- tetrahydrocannabinol in man Eur. J. Pharmacol. 28 1974 172 177
11. H.W. Kosterlitz, and S.J. Paterson Opioid receptors and mechanisms of opioid analgesia C. Benedetti C.R. Chapman G. Giron Advances in pain research and therapy vol. 14 1990 Raven Press New York 37 43
12. I. von Kügelgen, and K. Starke Noradrenaline-ATP co-transmission in the sympathetic nervous system Trends Pharmacol. Sci. 12 1991 319 324
13. 1 cannabinoid receptors Br. J. Pharmacol. 134 2001 161 167
14. 2 or EDG-1 Eur. J. Pharmacol. 489 2004 21 27
15. 1 receptors: similarities to presynaptic imidazoline and edg receptors Neurochem. Int. 40 2002 157 167
16. L. Offertáler, F.-M. Mo, S. Bátkai, J. Liu, M. Begg, R.K. Razdan, B.R. Martin, R.D. Bukoski, and G. Kunos Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor Mol. Pharmacol. 63 2003 699 705
17. S.E. O'Sullivan, D.A. Kendall, and M.D. Randall Characterisation of the vasorelaxant properties of the novel endocannabinoid N-arachidonoyl-dopamine (NADA) Br. J. Pharmacol. 141 2004 803 812
18. R.G. Pertwee The central neuropharmacology of psychotropic cannabinoids Pharmacol. Ther. 36 1988 189 261
19. 8- tetrahydrocannabinol in two isolated tissue preparations Eur. J. Pharmacol. 315 1996 195 201
20. 2 receptors Pharmacol. Ther. 74 1997 129 180
21. R.G. Pertwee The pharmacology and therapeutic potential of cannabidiol V. Di Marzo Cannabinoids 2004 Kluwer Academic/Plenum Publishers 32 83 〈http://www.eurekah.com/〉 2004
22. R.G. Pertwee Novel pharmacological targets for cannabinoids Curr. Neuropharmacol. 2 2004 9 29
23. R.G. Pertwee, G. Griffin, J.A.H. Lainton, and J.W. Huffman Pharmacological characterization of three novel cannabinoid receptor agonists in the mouse isolated vas deferens Eur. J. Pharmacol. 284 1995 241 247
24. R.G. Pertwee, R.A. Ross, S.J. Craib, and A. Thomas (-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens Eur. J. Pharmacol. 456 2002 99 106
25. M. Rinaldi-Carmona, F. Barth, J. Millan, J.-M. Derocq, P. Casellas, C. Congy, D. Oustric, M. Sarran, M. Bouaboula, B. Calandra, M. Portier, D. Shire, J.-C. Brelière, and G. Le Fur SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor J. Pharmacol. Exp. Ther. 284 1998 644 650
26. R.A. Ross, T.M. Gibson, H.C. Brockie, M. Leslie, G. Pashmi, S.J. Craib, V. Di Marzo, and R.G. Pertwee Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens Br. J. Pharmacol. 132 2001 631 640
27. E.B. Russo Introduction: cannabis: from pariah to prescription J. Cannabis Ther. 3 3 2003 1 29
28. E. Schlicker, and M. Kathman Modulation of transmitter release via presynaptic cannabinoid receptors Trends Pharmacol. Sci. 22 2001 565 572
29. 2-adrenoceptors J. Neurochem. 78 2001 685 693
30. Thomas, A., Craib, S. J., Ross, R. A., Pertwee, R. G., 2002. Cannabidiol attenuates responses of the mouse vas deferens to cannabinoid and non-cannabinoid receptor agonists. In: 2002 Symposium on the Cannabinoids. International Cannabinoid Research Society, Burlington, Vermont, p. 78.
31. 1 receptor antagonist Eur. J. Pharmacol. 487 2004 213 221
32. 3H-noradrenaline release by presynaptic opioid, cannabinoid and bradykinin receptors and β-adrenoceptors in mouse tissues Br. J. Pharmacol. 130 2000 321 330
33. J.A. Wagner, K. Varga, Z. Járai, and G. Kunos Mesenteric vasodilation mediated by endothelial anandamide receptors Hypertension 33 1999 429 434
34. B.A. Whittle, G.W. Guy, and P. Robson Prospects for new cannabis-based prescription medicines J. Cannabis Ther. 1 3-4 2001 183 205
35. 9-THC in normal subjects Psychopharmacology 76 1982 245 250
36. 2 cannabinoid receptor- independent mechanism J. Neurosci. 22 2002 4720 4727